STERIS plc stock holds steady as investors digest fiscal 2026 outlook

Published on 09/15/2026 at 13:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

STERIS plc stock trades around the USD 213 mark as of September 14, 2026, with a market cap near USD 25.8 billion. Fiscal 2026 revenue from continuing operations rose 9 percent to USD 5.94 billion compared with the prior year.

Fotorealistische Sterilisationsabteilung mit Autoklav und Instrumententabletts im Krankenhaus — Steris plc IE00BFY8C754 zeigt fotorealistisch eine moderne Krankenhaus-Sterilisationsabteilung mit Edelstahl-Autoklaven und Instrumentenwagen, Illustration mit AI erstellt.

STERIS plc stock (ISIN IE00BFY8C754) is trading near USD 213 on the New York Stock Exchange as of September 14, 2026, giving the healthcare sterilization specialist a market capitalization of about USD 25.8 billion.

Fiscal 2026 results and outlook

According to Stock Titan in a summary of STERIS plc filings on September 15, 2026, the company reported revenue from continuing operations of USD 5.94 billion for fiscal 2026, an increase of 9 percent versus the prior year.

The same summary notes that constant currency organic revenue grew 7 percent in fiscal 2026, underscoring that most of the top-line expansion came from underlying demand rather than foreign-exchange effects, which is relevant for investors assessing the sustainability of growth.

Most recent quarterly comparison

In its Form 8-K covering results for the quarter ended September 30, 2025, which corresponds to STERIS plc's fiscal 2026 second quarter, the company reported financial performance that contributed to the full-year growth profile, although detailed quarterly figures are not reiterated in the recent highlights from Stock Titan.

For investors, the key comparison is that fiscal 2026 revenue from continuing operations at USD 5.94 billion stands meaningfully above the prior year's level, with the 9 percent growth rate signaling mid-single to high-single-digit underlying demand when adjusted for currency, as indicated by the 7 percent constant currency organic expansion.

Valuation and analyst context

Data from Stock Analysis on September 14, 2026, put STERIS plc's market capitalization at USD 25.79 billion, aligning with the roughly USD 25.8 billion level implied by its share price around USD 213.

The same overview reports an average analyst price target of USD 268.25 for STERIS plc, which is about 2.1 percent above the current share price cited there, suggesting that, in aggregate, covering analysts see limited upside from present levels rather than a deep discount or a severe overvaluation.

Upcoming earnings dates

Earnings-calendar data from AltIndex as of September 14, 2026, indicate that STERIS plc is scheduled to report its next set of quarterly results on November 3, 2026, giving investors a clear near-term milestone to reassess the fiscal 2027 trajectory.

AltIndex notes that the stock is trading at USD 213.66, up 7.5 percent over the last three months from USD 198.79, which shows a moderate share price appreciation ahead of the upcoming earnings release and reflects a market that has gradually warmed to the fiscal 2026 performance.

Stock price level and trading venue

As of September 14, 2026, STERIS plc stock trades on the New York Stock Exchange at around USD 213 per share, with the NYSE quote serving as the primary reference price for investors assessing valuation and performance relative to healthcare peers.